Free Trial

argenx (ARGX) Stock Price, News & Analysis

-4.92 (-1.36%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
168,227 shs
Average Volume
308,311 shs
Market Capitalization
$21.20 billion
P/E Ratio
Dividend Yield
Price Target

argenx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
47.1% Upside
$524.68 Price Target
Short Interest
2.46% of Shares Sold Short
Dividend Strength
News Sentiment
0.74mentions of argenx in the last 14 days
Based on 8 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.57) to $2.32 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

334th out of 921 stocks

Biological Products, Except Diagnostic Industry

45th out of 152 stocks

ARGX stock logo

About argenx Stock (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Stock Price History

ARGX Stock News Headlines

argenx SE (ARGX)
Stifel Nicolaus Keeps Their Buy Rating on Argenx Se (ARGX)
argenx (NASDAQ:ARGX) Price Target Cut to $448.00
argenx (NASDAQ:ARGX) Price Target Cut to $468.00
Breaking Down argenx: 12 Analysts Share Their Views
Argenx SE Q1 2024 Earnings Preview
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
21 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.27 billion
Book Value
$69.22 per share


Free Float
Market Cap
$21.29 billion
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 52)
    M.Sc., CEO & Executive Director
    Comp: $1.29M
  • Mr. Karl Gubitz (Age 54)
    Chief Financial Officer
    Comp: $843.26k
  • Ms. Karen Massey (Age 45)
    Chief Operating Officer
    Comp: $1.42M
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Mr. Peter Ulrichts (Age 44)
    Chief Scientific Officer
  • Ms. Beth DelGiacco
    VP and Global Head of Corporate Communications & Investor Relations
  • Ms. Malini Moorthy (Age 54)
    General Counsel
  • Mr. Arjen Lemmen M.Sc. (Age 39)
    Vice President of Corporate Development & Strategy
  • Mr. Marc Schorpion (Age 65)
    Global Head of Human Resources
  • Ms. Andria Wilk (Age 50)
    Global Head of Quality

ARGX Stock Analysis - Frequently Asked Questions

Should I buy or sell argenx stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 sell rating, 5 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price target for 2024?

21 brokers have issued 1 year price targets for argenx's stock. Their ARGX share price targets range from $408.00 to $641.00. On average, they expect the company's stock price to reach $524.68 in the next year. This suggests a possible upside of 47.1% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2024?

argenx's stock was trading at $380.43 at the start of the year. Since then, ARGX shares have decreased by 6.3% and is now trading at $356.62.
View the best growth stocks for 2024 here

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our ARGX earnings forecast

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its quarterly earnings data on Monday, May, 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $0.33. The company earned $412.51 million during the quarter, compared to analyst estimates of $404.03 million. argenx had a negative trailing twelve-month return on equity of 14.14% and a negative net margin of 22.58%. During the same period in the previous year, the business earned ($0.52) earnings per share.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

argenx (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.26%), Janus Henderson Group PLC (3.73%), Capital World Investors (3.14%), Avoro Capital Advisors LLC (2.08%), Bellevue Group AG (1.36%) and Clearbridge Investments LLC (1.00%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARGX) was last updated on 5/21/2024 by Staff

From Our Partners